The 20th annual Rice Business Plan Competition took place virtually from June 17 to 19 and awarded over $1.2 million in investment and cash prizes. Photo courtesy of Rice University

For the 20th year, the Rice Business Plan Competition has awarded prizes and investments to student-led startups from around the ward. While this year's competition was postponed and virtually held, the show went on with 42 startups pitching virtually June 17 to 19.

After whittling down the 42 startups to seven finalists, the RBPC judges named the winners. And, this year, all seven finalists walked away with a monetary prize. Here's how the finalists cleaned up.

  • Aurign, which provides publishing services for recording artists and record labels, from Georgia State University, won first place and the $350,000 grand prize from GOOSE Capital. Aurign also won RG Advisory Partners' prize of $25,000, bringing the company's total to $375,000 won.
  • Coming in second place with a $100,000 investment prize (awarded by Finger Interests, Anderson Family Fund, Greg Novak, and Tracy Druce) was Dartmouth College's nanopathdx, which is creating diagnostic tools for chronic and infectious diseases. Nanopathdx won two other monetary prizes — the $25,000 Spirit of Entrepreneurship Prize from Pearland Economic Development and Ncourage's $25,000 award focused on female entrepreneurs — for a total of $150,000 won. The company also won the Palo Alto Software Live Plan award and an award from SheSpace.
  • Harvard University's Fractal — a cloud computing tech company that enables powerful remote work tools — won third place and a $50,000 investment from Finger Interests, Anderson Family Fund, Greg Novak, and Tracy Druce. The company also won an $100,000 investment from the Houston Angel Network, bringing their total prize to $150,000.
  • In fourth place was RefresherBoxx from RWTH Aachen University in Germany. The company has created disinfecting devices for clothing and recently pivoted to create a COVID-19 application. The startup won a $5,000 prize sponsored by Norton Rose Fulbright for placing in the finals, but also walked away with a $100,000 investment from TiE Houston Angels, bringing the startup's total prize money to $105,000.
  • The University of Chicago's Beltech, which has created a safer, longer lasting battery, won fifth place and a $5,000 award sponsored by EY. The company also won an $100,000 investment from the Houston Angel Network, bringing the total amount won to to $105,000.
  • Cardiosense from Northwestern University, which has created a wearable heart monitor device, took sixth place in the competition and won a $5,000 award sponsored by Chevron Technology Ventures. Cardiosense also won two other monetary prizes — TMC Innovation's $100K TMC Healthcare Innovation investment and NASA's $25,000 Human Health and Performance Award — bringing the total amount won to $130,000. The company also won OFW Law's prize.
  • Relavo, a safer home dialysis treatment company from Johns Hopkins University, came in seventh place and won a $5,000 prize sponsored by Shell Ventures. Relavo also won three other monetary prizes — the $25,000 Pediatric Device Prize from the Southwest National Pediatric Device Consortium, Ncourage's $25,000 award focused on female entrepreneurs, and Polsinelli's $15,000 technology prize — bringing the startup's total prize money to $70,000.
Some of the competition's participating startups outside of the seven finalists won monetary prizes. Here's a list of those.
  • BIOMILQ, a female-founded startup out of Duke University that can cultivate breast milk outside of the body, won The Artemis Fund's $100,000 prize.
  • The University of Maryland's Algen Air — a natural air purifier that uses algae to filter air — won NASA's $25,000 Space Exploration Award.
  • SlumberFlow — a sleep apnea treatment device from the University of Michigan — won the the $25,000 Pediatric Device Prize from the Southwest National Pediatric Device Consortium.
  • Rice University's own EVA, which streamlines vascular access for medical professionals, won the Texas Business Hall of Fame's $25,000 prize.
  • Contraire — a predictive analysis control system for aeration process within municipal wastewater treatment plants — from Oklahoma State University won Polsinelli's $15,000 Energy Innovation prize.
While not ready to name investment recipients at the virtual event, the Owl Investment Group announced they will be inviting some companies to pitch to them directly.
Additional non-monetary prizes included:
  • Capital Factory's Golden Ticket prize to EVA from Rice University, NanoCare from Texas State University, and SeebeckCell Technologies from the University of Texas at Arlington.
  • Mercury Fund's Elevator Pitch winners included: KnoNap from Georgetown University (first place), Steeroflex from the University of California San Diego (second place), Encapsulate from the University of Connecticut (third place), RefresherBoxx (fourth place), and NanoCare from Texas State University (fifth place).
The virtual event wrapped up with the announcement of the 21st annual RBPC, which is set for April 8 to 10 next year.
Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

New Houston biotech co. lands $30M for pulmonary fibrosis drug

drug money

Most of us can claim a scar or two on our bodies. But when scarring develops inside the body, it’s known as a fibrotic disorder. A freshly launched Houston company, Oorja Bio Inc., is working on a treatment that can help to repair cells and reduce the damage wrought by the growth of fibrotic tissue in patients.

Late last month, Oorja Bio hit the scene with a pair of big announcements. Not only has the company raised a $30 million Series A thanks to founding investor California-based Westlake BioPartners, but it has also already paved the way for a Phase 2 study to take place this year.

Oorja Bio received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA), allowing the company to test its treatment in patients with idiopathic pulmonary fibrosis (IPF), a scarring of the lung tissue. IPF affects more than 150,000 adults in the United States and can result in a range of symptoms from shortness of breath to organ failure and death as it progresses.

Oorja Bio’s lead drug candidate, ORJ-001, was shown in a Phase 1 in-human trial to demonstrate “therapeutically relevant exposure and favorable tolerability” in 64 healthy adult volunteers in whom it was administered daily or weekly, according to a news release. Pre-clinical studies of ORJ-001 showed durable target tissue engagement and biomarker activity in bleomycin-induced lung fibrosis.

Administered subcutaneously, ORJ-001 is intended to improve and even restore function in cells that can reduce the signaling that causes IPF. It stops advancement of IPF and also allows for tissue repair. Currently available treatments for the disease can slow the development of IPF down, but do not address the declining lung function that’s inherent in its progression.

“The clinical and preclinical results from our studies to date give us confidence that ORJ-001 represents a novel treatment approach with the potential to repair and reverse fibrosis and modify disease progression in IPF,” Dr. Janethe Pena, CMO of Oorja Bio, said in the release.

“Our team is energized to deliver on our goal of redefining the future of fibrotic diseases, beginning with ORJ-001,” CEO and founder Sujay Kango added. “As we advance ORJ-001 in the clinic, we are embracing the paradigm shift in our biological understanding of IPF pathology that aligns with the central role of the alveolar epithelium. ORJ-001 was designed with this biology in mind and may provide, for the first time, a therapeutic intervention that repairs and reverses fibrosis and promotes disease modification.”

Most patients live only three to five years following their IPF diagnosis. Soon, ORJ-001 and Oorja Bio could give them a fighting chance.

Axiom Space tops $525M in oversubscribed round, announces Swiss subsidiary

funding boost

Axiom Space tacked on an additional $175 million to a previously announced capital raise, bringing the oversubscribed round to a total of more than $525 million.

Axiom shared in February that it had secured $350 million in a financing round led by Type One Ventures and Qatar Investment Authority. In the latest release from the company, Axiom reports that Japan-based MUFG Bank Ltd. joined the round as a new investor, in addition to continued participation from existing backers.

The funding will go toward developing the company's commercial space station, known as Axiom Station, and the production of its Axiom Extravehicular Mobility Unit (AxEMU) under its NASA spacesuit contract.

“Investor interest in this round outpaced what we set out to raise, which speaks to the moment we’re in,” Jonathan Cirtain, CEO and president of Axiom Space, said in the news release. “Our partners see what is possible in low-Earth orbit, and they see who is positioned to lead it.”

Axiom announced last month that it planned to open a Japanese subsidiary July 1. Earlier this week, it also shared plans to establish Axiom Space Switzerland, a wholly owned subsidiary based in Lucerne that is also expected to begin operations this summer.

The Switzerland subsidiary aims to establish Axiom's presence in Europe and help it partner with the European Space Agency and other space organizations and companies on the continent.

“Europe is a founding leader in the creation of the commercial space economy, and Switzerland is uniquely positioned to convene the government agencies, research institutions, and industrial entities that will shape its next decade,” Cirtain added in a separate release. “Axiom Space Switzerland facilitates the scaling of development and deployment of the infrastructure that will succeed the International Space Station.”

Texas cashes in among 10 best U.S. state economies in 2026 report

State Economics

A new study gauging the success or decline in economic performance in every state has revealed Texas' economy remains stable in 2026 after it dropped out of the top five to No. 8 last year.

Texas boasts the No. 8 best state economy in the U.S. this year, according to WalletHub's annual "Best & Worst State Economies" report. The personal finance website's analysts ranked all 50 states and the District of Columbia across 28 relevant metrics to measure each state's economic activity and health status, and its "innovation potential."

Notably, Texas leads the nation for the most exports per capita in the U.S. in a five-way tie with Louisiana, Kentucky, North Dakota, and Indiana. Across the study's three main categories, Texas ranked highly for its economic activity (No. 7) and economic health (No. 11), and the state's "innovation potential" rank is the 24th best in the nation.

This is how WalletHub ranked Texas' economic performance, where No. 1 is considered the best and No. 25 is considered average:
  • No. 6 – Change in non-farm payrolls
  • No. 8 – Change in GDP
  • No. 8 – Startup activity
  • No. 11 – Annual median household income
  • No. 18 – Government surplus/deficit per capita
  • No. 21 – Percentage of jobs in high-tech industries
  • No. 30 – Unemployment rate
WalletHub previously ranked Texas one of the top three states to start a business in 2026, with Houston earning its own entrepreneurial acclaim in separate rankings of the best big cities for new businesses and for starting a career.

"U.S. economic growth depends heavily on the performance of individual states, and some contribute more than others," the report's author wrote. "For example, California, Texas, New York and Florida have economies so large that if they were countries, they would rank in the top 20 in the world."

The five states with the worst state economies in 2026 are Rhode Island (No. 47), Maine (No. 48), Louisana (No. 49), Kentucky (No. 50), and West Virginia (No. 51).

The top 10 best state economies for 2026 are:

  • No. 1 – Massachusetts
  • No. 2 – Washington
  • No. 3 – Utah
  • No. 4 – California
  • No. 5 – Delaware
  • No. 6 – North Carolina
  • No. 7 – New York
  • No. 8 – Texas
  • No. 9 – Colorado
  • No. 10 – Florida

---

This article originally appeared on CultureMap.com.